This raises the possibility that concurrent or subsequent blockade of PD-L1 added to PD-1 treatment may block the salvage mechanism of anti-PD-1-injured myocytes, leading to the development of fulminant myocarditis. The gene discussed is CD274; the disease is myocarditis.